Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Cortes

Showing results (201-210 of 231) with videos related to

Pageof 24
Sort By:
The New England Journal of Medicine|December 12, 2019
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast CancerShanu Modi, Cristina Saura, Toshinari Yamashita, et al.
The Lancet. Oncology|May 1, 2018
Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trialSonia Pernas, Miguel Martin, Peter A Kaufman, et al.
The Lancet. Oncology|August 30, 2024
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trialMafalda Oliveira, Hope S Rugo, Sacha J Howell, et al.
Science (New York, N.Y.)|November 9, 2019
Collaboration across boundaries in the AmazonPaula Ribeiro Prist, Noam Levin, Jean Paul Metzger, et al.
Nature Medicine|January 21, 2025
Pembrolizumab and chemotherapy in high-risk, early-stage, ER<sup>+</sup>/HER2<sup>-</sup> breast cancer: a randomized phase 3 trialFatima Cardoso, Joyce O'Shaughnessy, Zhenzhen Liu, et al.
ESMO Open|August 28, 2020
Oncological care organisation during COVID-19 outbreakConcetta Elisa Onesti, Hope S Rugo, Daniele Generali, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2026
PI3K inhibition in combination with tamoxifen in patients with metastatic HR+/HER2- breast cancer: clinical and circulating tumor DNA resultsRosie A B Voorthuis, Mafalda Oliveira, Annelot G J van Rossum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2023
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast CancerMarion T van Mackelenbergh, Sibylle Loibl, Michael Untch, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 20, 2023
Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO)Orit Kaidar-Person, Icro Meattini, Liesbeth J Boersma, et al.
Oncotarget|May 15, 2018
Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastasesLeticia De Mattos-Arruda, Charlotte K Y Ng, Salvatore Piscuoglio, et al.
Pageof 24

Showing results (201-210 of 231) with videos related to

Sort By:
Pageof 24
The New England Journal of Medicine|December 12, 2019
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast CancerShanu Modi, Cristina Saura, Toshinari Yamashita, et al.
The Lancet. Oncology|May 1, 2018
Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trialSonia Pernas, Miguel Martin, Peter A Kaufman, et al.
The Lancet. Oncology|August 30, 2024
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trialMafalda Oliveira, Hope S Rugo, Sacha J Howell, et al.
Science (New York, N.Y.)|November 9, 2019
Collaboration across boundaries in the AmazonPaula Ribeiro Prist, Noam Levin, Jean Paul Metzger, et al.
Nature Medicine|January 21, 2025
Pembrolizumab and chemotherapy in high-risk, early-stage, ER<sup>+</sup>/HER2<sup>-</sup> breast cancer: a randomized phase 3 trialFatima Cardoso, Joyce O'Shaughnessy, Zhenzhen Liu, et al.
ESMO Open|August 28, 2020
Oncological care organisation during COVID-19 outbreakConcetta Elisa Onesti, Hope S Rugo, Daniele Generali, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2026
PI3K inhibition in combination with tamoxifen in patients with metastatic HR+/HER2- breast cancer: clinical and circulating tumor DNA resultsRosie A B Voorthuis, Mafalda Oliveira, Annelot G J van Rossum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2023
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast CancerMarion T van Mackelenbergh, Sibylle Loibl, Michael Untch, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 20, 2023
Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO)Orit Kaidar-Person, Icro Meattini, Liesbeth J Boersma, et al.
Oncotarget|May 15, 2018
Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastasesLeticia De Mattos-Arruda, Charlotte K Y Ng, Salvatore Piscuoglio, et al.
Pageof 24